Activist manager Sahm Adrangi’s firm has had a tough year, in part due to a big short bet against Dish Network.
July 28, 2016
Photo credit: BloombergBy Michelle Celarier When Zafgen, a small Boston biotechnology company, said in late July that it was suspending production of a weight-loss drug that has drawn scrutiny from the Food and Drug
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.